Sunday, October 18, 2026

Back to today

From X

2026.42: Home At Last

Stratechery’s weekly bundle covers Apple HomeView and SpaceX’s cellular ambitions.

SLS · short

Sellas Life Sciences Group I

SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.

Deep Dive: XPEL

XPEL sells paint-protection film and DAP cutting software, using 90,000-plus vehicle templates to win share from 3M and Eastman.

Cerebras June 2026 Earnings

Cerebras faces shareholder criticism over $700,000 to $850,000 WSE-3 rack pricing, alleged packaging-yield losses and SRAM-based KV-cache…

Publications we follow

Every publication on this site, hand-picked.

128 publications

Newsletters 108

X accounts we follow

Every account on this site, hand-picked.

90 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.